Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05173272

Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer

A Prospective Randomized Controlled Trials of Neoadjuvant Chemotherapy Combined With Serplulimab Followed by Concurrent Chemoradiation Versus Concurrent Chemoradiation Therapy Alone in Advanced Cervical Cancer

Sponsor: Sichuan Cancer Hospital and Research Institute

Conditions Cervical Cancer

Interventions Brachytherapy CCRT Neoadjuvant Therapy

Updated 8 times since 2022 Last updated: Dec 25, 2023 Started: Jul 24, 2023 Primary completion: Dec 28, 2027 Completion: Dec 28, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cervical Cancer and is currently actively recruiting participants. Sichuan Cancer Hospital and Research Institute leads this study, which shows 8 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Jul 2024 [monthly]

Recruiting PHASE3
Jul 2023 — Jan 2024 [monthly]

Recruiting PHASE3
May 2023 — Jul 2023 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting

▶ Show 3 earlier versions

Dec 2022 — May 2023 [monthly]

Not Yet Recruiting PHASE3
Sep 2022 — Dec 2022 [monthly]

Not Yet Recruiting PHASE3
Jan 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sichuan Cancer Hospital and Research Institute

Data source: Sichuan Cancer Hospital and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China